Abstract
The flexible and efficient enantioselective synthesis of poison-frog alkaloids has been described using the highly stereoselective conjugate addition reactions as the key step. Several 5,8-disubstituted indolizidines and 1,4-disubstituted quinolizidines have been synthesized according to this strategy. Furthermore, 5,6,8-trisubstituted indolizidne type of poison-frog alkaloid 223A and unique tricyclic poison-frog alkaloid 205B have also been synthesized by sequential use of the above key conjugate addition reaction. Investigations of inhibitory effects of synthetic poison-frog alkaloids on neuronal nicotinic acetylcholine receptors have been conducted, and we found that most of the synthetic compounds showed inhibitory effects on the neuronal nicotinic acetylcholine receptors. Especially, the 5,8-disubstituted indolizidine 235B inhibited the α4 β2-neuronal nicotinic acetylcholine receptors in highly subtype-selective manner. These results suggested that the synthetic alkaloid 235B is a promising lead compound for the drugs designed to treat cholinergic disorders such as autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE).
Keywords: Michael-type conjugate addition, indolizidine, quinolizidine, piperidone synthesis, nicotinic acetylcholine receptors (nAChRs)
Current Chemical Biology
Title: Synthesis of Poison-Frog Alkaloids and Their Pharmacological Effects at Neuronal Nicotinic Acetylcholine Receptors
Volume: 1 Issue: 1
Author(s): Naoki Toyooka, Hiroshi Tsuneki, Soushi Kobayashi, Zhou Dejun, Masashi Kawasaki, Ikuko Kimura, Toshiyasu Sasaoka and Hideo Nemoto
Affiliation:
Keywords: Michael-type conjugate addition, indolizidine, quinolizidine, piperidone synthesis, nicotinic acetylcholine receptors (nAChRs)
Abstract: The flexible and efficient enantioselective synthesis of poison-frog alkaloids has been described using the highly stereoselective conjugate addition reactions as the key step. Several 5,8-disubstituted indolizidines and 1,4-disubstituted quinolizidines have been synthesized according to this strategy. Furthermore, 5,6,8-trisubstituted indolizidne type of poison-frog alkaloid 223A and unique tricyclic poison-frog alkaloid 205B have also been synthesized by sequential use of the above key conjugate addition reaction. Investigations of inhibitory effects of synthetic poison-frog alkaloids on neuronal nicotinic acetylcholine receptors have been conducted, and we found that most of the synthetic compounds showed inhibitory effects on the neuronal nicotinic acetylcholine receptors. Especially, the 5,8-disubstituted indolizidine 235B inhibited the α4 β2-neuronal nicotinic acetylcholine receptors in highly subtype-selective manner. These results suggested that the synthetic alkaloid 235B is a promising lead compound for the drugs designed to treat cholinergic disorders such as autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE).
Export Options
About this article
Cite this article as:
Toyooka Naoki, Tsuneki Hiroshi, Kobayashi Soushi, Dejun Zhou, Kawasaki Masashi, Kimura Ikuko, Sasaoka Toshiyasu and Nemoto Hideo, Synthesis of Poison-Frog Alkaloids and Their Pharmacological Effects at Neuronal Nicotinic Acetylcholine Receptors, Current Chemical Biology 2007; 1 (1) . https://dx.doi.org/10.2174/2212796810701010097
DOI https://dx.doi.org/10.2174/2212796810701010097 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dysiherbaine: A New Generation of Excitatory Amino Acids of Marine Origin
Central Nervous System Agents in Medicinal Chemistry Alkaptonuria, Ochronosis and Ochronotic Arthropathy in Mainland France and the Reunion Island. A Report of Clinical and Molecular Findings in 29 Patients
Current Rheumatology Reviews Truly “Rational” Polytherapy: Maximizing Efficacy and Minimizing Drug Interactions, Drug Load, and Adverse Effects
Current Neuropharmacology Neural Progenitors and HIV-1- Associated Central Nervous System Disease in Adults and Children
Current HIV Research Trafficking of Neuronal Two Pore Domain Potassium Channels
Current Neuropharmacology Inflammation and Neurogenesis in Temporal Lobe Epilepsy
Current Drug Targets - CNS & Neurological Disorders Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimers Disease
Current Drug Targets Cognitive Identity in Schizophrenia: Vision, Space, and Body Perception from Prodrome to Syndrome
Current Psychiatry Reviews Postnatal Neurogenesis and Dopamine Alterations in Early Psychosis
Recent Patents on CNS Drug Discovery (Discontinued) Synthesis, Antifungal Activity and Carbonic Anhydrase Inhibitory Properties of Cu (II) Bis (3, 4 Dimethoxybenzoate) Bis (Nicotinamide) Dihydrate
Current Enzyme Inhibition HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology The Control of Male Sexual Responses
Current Pharmaceutical Design Relevance of Excitable Media Theory and Retinal Spreading Depression Experiments in Preclinical Pharmacological Research
Current Neuropharmacology Anesthetic Considerations for Electroconvulsive Therapy-Especially Hemodynamic and Respiratory Management
Current Psychiatry Reviews SIRT1 Promotes Neuronal Fortification in Neurodegenerative Diseases through Attenuation of Pathological Hallmarks and Enhancement of Cellular Lifespan
Current Neuropharmacology Molecular Biology of T-Type Calcium Channels
CNS & Neurological Disorders - Drug Targets Ethnobotanical Treatment Strategies Against Alzheimers Disease
Current Alzheimer Research Editorial (Thematic Issue: Global Trends for Nanotechnological Approaches in Various Health Issues - Part 1)
Current Drug Metabolism